SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-02-12
Accession Number: 0001493152-26-006407
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226006407/forms-1.htm

Chunk 29 of 83
Word Count: 1416
Character Count: 9136

Document Content:

other public announcements and filings with the SEC; ● rumors and market speculation involving us or other companies in our industry; ● actual or anticipated changes in our results of operations or fluctuations in our results of operations; ● actual or anticipated developments in our business, our competitors’ businesses or the competitive landscape generally; ● litigation involving us, our industry, or both, or investigations by regulators into our operations or those of our competitors; ● developments or disputes concerning our intellectual property or other proprietary rights; ● announced or completed acquisitions of businesses, product candidates, services or technologies by us or our competitors; ● new laws or regulations or new interpretations of existing laws or regulations applicable to our business; ● changes in accounting standards, policies, guidelines, interpretations or principles; ● any significant change in our management; and ● general economic conditions and slow or negative growth of our markets.

recent years, the stock markets generally have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate
to the operating performance of listed companies. Broad market and industry factors may significantly affect the market price of our
common stock, regardless of our actual operating performance. These fluctuations may be even more pronounced in the trading market for
our common stock shortly following this offering. If the market price of shares of our common stock after this offering does not ever
exceed the initial public offering price, you may not realize any return on your investment in us and may lose some or all of your investment.

addition, in the past, following periods of volatility in the overall market and in the market price of a particular company’s
securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against
us, could result in substantial costs and a diversion of our management’s attention and resources.

Certain
recent initial public offerings of companies with public floats comparable to our anticipated public float have experienced extreme volatility
that was seemingly unrelated to the underlying performance of the respective company. We may experience similar volatility, which may
make it difficult for prospective investors to assess the value of our common stock.

addition to the risks addressed above in “Risks Relating to Our Securities and this Offering — The trading price of our
common stock may be volatile, and you could lose all or part of your investment,” our common stock may be subject to extreme
volatility that is seemingly unrelated to the underlying performance of our business. Recently, companies with comparable public floats
and initial public offering sizes have experienced instances of extreme stock price run-ups followed by rapid price declines, and such
stock price volatility was seemingly unrelated to the respective company’s underlying performance. Although the specific cause
of such volatility is unclear, our anticipated public float may amplify the impact the actions taken by a few stockholders have on the
price of our common stock, which may cause the price of our common stock to deviate, potentially significantly, from a price that better
reflects the underlying performance of our business. Should our common stock experience run-ups and declines that are seemingly unrelated
to our actual or expected operating performance and financial condition or prospects, prospective investors may have difficulty assessing
the rapidly changing value of our common stock. In addition, investors of shares of our common stock may experience losses, which may
be material, if the price of our common stock declines after this offering or if such investors purchase shares of our common stock prior
to any price decline.

securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price
and trading volume could decline.

The
trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about
us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. If no securities
or industry analysts commence coverage of our company, the trading price for our stock would be negatively impacted. If we obtain securities
or industry analyst coverage and if one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable
research about our business, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to
publish reports on us regularly, demand for our stock could decrease, which could cause our stock price and trading volume to decline.

Future
sales of our common stock or securities convertible, exchangeable or exercisable into our common stock may depress our stock price.

Sales
of a substantial number of shares of our common stock or securities convertible, exchangeable or exercisable into our common stock
in the public market after the completion of this offering, or the perception that these sales could occur, could adversely affect the
market price of our common stock and could materially impair our ability to raise capital through equity offerings in the future.

The
common stock sold in this offering will be freely tradable without restriction or further registration under the Securities Act of 1933,
as amended (the “Securities Act”), and shares held by our existing stockholders may also be sold in the public market in
the future subject to the restrictions in Rule 144 under the Securities Act and the applicable lock-up agreements. Following the consummation
of this offering, assuming no exercise of outstanding options or the Representative’s Warrant, there will be
shares of common stock outstanding immediately after this offering assuming full exercise of the underwriters’ over-allotment option,
and shares of common stock assuming no exercise of the underwriters’ over-allotment option, including 7,664,988 shares of
common stock being issued upon the closing of this offering in connection with the conversion of: (i) 1,565,000 shares of our existing
Series A Preferred Stock into 1,565,000 shares of common stock (assuming an initial public offering price of at least $10.00 and an
assumed conversion price of $10.00) and (ii) $11,333,146 of our existing convertible notes into 6,099,988 shares of
our common stock (assuming an initial public offering price of at least $10.00 and an assumed conversion price of $10.00). In
connection with this offering, we and each of our directors and officers named in the section “Management,” and our
existing stockholders have agreed not to sell shares of common stock for a period of six (6) months from the date of the closing of this
offering without the prior written consent of the representative of the underwriters, subject to customary exceptions. The representative
of the underwriters may release these securities from lock-up restrictions at any time, subject to applicable regulations of the Financial
Industry Regulatory Authority, Inc. (“FINRA”). We cannot predict what effect, if any, market sales of securities held by
our significant stockholders or any other stockholder or the availability of these securities for future sale will have on the market
price of our common stock. See “Underwriting” and “Shares Eligible for Future Sale” for a more
detailed description of the restrictions on selling our securities after this offering.

Our
failure to meet the continued listing requirements of Nasdaq could result in a delisting of our common stock.

There
is a risk that our securities will not continue to be listed on Nasdaq even if our securities are listed on Nasdaq. Following this offering,
in order to maintain our listing on Nasdaq, we will be required to comply with certain Nasdaq continuing listing rules, including those
regarding minimum stockholders’ equity, minimum share price, minimum market value of publicly held shares, corporate governance
and various additional requirements. If we are unable to satisfy Nasdaq criteria for maintaining our listing, our securities could be
subject to delisting. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability
to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action
taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market
price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement
or prevent future non-compliance with Nasdaq’s listing requirements.

Our
management will have broad discretion in how we use the net proceeds from this offering and might not use them effectively.